Optivar®
azelastine hydrochloride 0.05% · ophthalmic solution
Allergy
Approved uses
Allergic conjunctivitis, ocular itching
1 drop in each affected eye BID
Itch relief begins within 3 minutes and lasts about 8 hours.
OFF-LABELNot in the FDA label for this product
Conjunctival redness of allergic conjunctivitis
1 drop in each affected eye BID, the labeled regimen, given for 6 weeks in the trial
RCT · n=139
Randomized 22-center trial in perennial allergic conjunctivitis (N=139) against masked placebo, with an open-label levocabastine arm: itching and conjunctival redness both improved versus placebo (P<0.001), the combined score improving 1.9 (SD 1.1) versus 0.6 (SD 1.1) on placebo at day 7 from a baseline of 3.7 to 3.8 on a 0 to 6 scale, and continuing to improve through day 42. Bitter taste and application site reaction were the most frequent adverse events. The US indication covers itching only, not redness.
Contraindications
Known or suspected hypersensitivity to any component of the solution.
6 mL solution in a 10 mL bottle, 0.05% (0.5 mg/mL)
Relatively selective histamine H1 antagonist and an inhibitor of the release of histamine and other mediators from cells (e.g. mast cells) involved in the allergic response. In-vitro studies using human cell lines have demonstrated inhibition of other mediators involved in allergic reactions (e.g. leukotrienes and PAF). Decreased chemotaxis and activation of eosinophils has also been demonstrated.
Warnings & Precautions
- Warnings: For ocular use only and not for injection or oral use.
- Soft contact lens wear: The benzalkonium chloride preservative may be absorbed by soft contact lenses. Patients whose eyes are not red should wait at least ten minutes after instillation before inserting soft lenses, and patients should not wear a contact lens if their eye is red.
- Contact lens related irritation: Should not be used to treat contact lens related irritation.
- Dropper tip contamination: To prevent contaminating the dropper tip and solution, do not touch any surface, the eyelids, or surrounding areas with the dropper tip. Keep bottle tightly closed when not in use.
Common Side Effects
In controlled multiple-dose studies where patients were treated for up to 56 days, the most frequently reported adverse reactions were transient eye burning/stinging (approximately 30%), headaches (approximately 15%) and bitter taste (approximately 10%). The occurrence of these events was generally mild. Asthma, conjunctivitis, dyspnea, eye pain, fatigue, influenza-like symptoms, pharyngitis, pruritus, rhinitis and temporary blurring were reported in 1% to 10% of patients. Some of these events were similar to the underlying disease being studied.
Pregnancy: Category C. Embryotoxic, fetotoxic and teratogenic (external and skeletal abnormalities) in mice at an oral 68.6 mg/kg/day (57,000 times the recommended ocular human use level); delayed ossification and increased 14th rib incidence in rats at 30 mg/kg/day (25,000 times), and resorption and fetotoxic effects in rats at 68.6 mg/kg/day (57,000 times). The relevance to humans of these skeletal findings noted at only high drug exposure levels is unknown. No adequate and well-controlled studies in pregnant women; use only if the potential benefit justifies the potential fetal risk.
Lactation: Excretion in human milk is unknown; caution in a nursing woman.
Safety and effectiveness below age 3 not established.